Teva Pharmaceutical Industries (NYSE:TEVA) Director Sells $14,358,456.00 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Teva Pharmaceutical Industries Trading Up 3.0%

TEVA opened at $40.18 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56. The firm has a market cap of $46.82 billion, a price-to-earnings ratio of 66.97, a PEG ratio of 4.93 and a beta of 0.87. Teva Pharmaceutical Industries Ltd. has a 12 month low of $18.21 and a 12 month high of $40.79. The stock has a fifty day moving average price of $36.04 and a 200-day moving average price of $33.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Oppenheimer initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday. They set an “outperform” rating and a $50.00 price objective for the company. Weiss Ratings downgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, September 8th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Leerink Partners started coverage on Teva Pharmaceutical Industries in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target on the stock. Finally, Barclays increased their price objective on Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $43.73.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Oppenheimer initiated coverage of Teva Pharmaceutical Industries with an “outperform” rating and a $50 price target, implying meaningful upside from recent trading levels. The firm cited a multi-year product launch cycle and Teva’s transition toward innovative biopharmaceuticals as potential growth drivers. Oppenheimer Teva coverage
• Positive Sentiment: Recent Phase 3 data for once-monthly olanzapine candidate TEV-749, along with additional data for UZEDY, supports investor interest in Teva’s long-acting injectable schizophrenia franchise. The program could create a future growth opportunity if regulatory approval is secured. Teva pipeline update
• Neutral Sentiment: Teva released a Q3 2026 aide-memoire containing previously disclosed information and scheduled its third-quarter earnings release for November 3, 2026, followed by a management conference call. The event gives investors a near-term catalyst, but no new financial guidance was provided. Teva Q3 2026 earnings announcement
• Neutral Sentiment: Short interest surged to approximately 31.5 million shares as of September 15, equal to about 2.7% of shares outstanding and 27.3 days of average trading volume. The positioning signals bearish bets, but could also amplify gains if short sellers cover.
• Negative Sentiment: Director Roberto Mignone sold 367,600 shares for approximately $14.36 million. Separately, Brian Savage sold 7,342 shares, while Teva insiders have recorded 17 sales and no purchases over the past six months. The pattern may weigh on investor confidence after the stock’s strong advance. Teva insider share sale

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. grew its position in Teva Pharmaceutical Industries by 2.2% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock worth $1,384,216,000 after purchasing an additional 1,004,941 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after buying an additional 5,917,423 shares during the last quarter. WCM Investment Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after buying an additional 26,813,522 shares during the last quarter. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $1,098,060,000. Finally, Geode Capital Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 10,326,504 shares of the company’s stock worth $320,295,000 after buying an additional 336,629 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.